However, after meta-analyzing data from three databases (CKDGen, FinnGen, Ebi), PCSK9 inhibitors and other drug targets were found to have no significant correlation with the risk of CKD occurrence (OR[95%]=0.1.16 [0.90-1.50]), reflecting the advantages of meta-analysis and the credibility of our results. The gene discussed is PCSK9; the disease is chronic kidney disease.